Which antibiotics are effective in treating E. coli septicemia in ducks? (Part 2)

In Part 2 of the topic “Treatment of E. coli Septicemia in Ducks,” Fivevet will continue to provide an in-depth analysis of the principles of antibiotic combination therapy, practical treatment regimen development, and supportive solutions to enhance disease control efficiency in modern duck farming. In addition, the article updates the current trends of antibiotic resistance in E. coli and suggests rational drug-use strategies to help farmers optimize treatment outcomes, reduce mortality rates, and sustainably protect duck flocks. II. Main antibiotic groups for the treatment of E. coli septicemia in ducks (continued)
4. Phenicol group The phenicol group inhibits protein synthesis by binding to the 50S ribosomal subunit, thereby suppressing the growth of E. coli bacteria. Bacterial resistance mainly occurs through drug efflux mechanisms associated with the floR gene. In addition, the enzyme chloramphenicol acetyltransferase (CAT) can inactivate the drug by attaching an acetyl group to the antibiotic molecule, altering its structure and preventing its binding to the ribosome; however, this mechanism mainly affects chloramphenicol and has limited impact on florfenicol.
In veterinary medicine, florfenicol is the preferred active ingredient due to its improved structure, which makes it less susceptible to inactivation by the CAT enzyme while maintaining good efficacy against many resistant strains. The drug has excellent tissue distribution, particularly in the lungs and air sacs, making it suitable for the treatment of respiratory infections and systemic bacterial infections. 5. Sulfonamide + Trimethoprim group The combination of sulfonamides and trimethoprim produces a synergistic effect by inhibiting two consecutive steps in the bacterial folic acid synthesis pathway, thereby preventing the synthesis of DNA and RNA.
Although this combination has good bactericidal activity, the current resistance rate of E. coli to this group is relatively high, mainly due to target enzyme modifications and other mechanisms such as increased PABA synthesis or reduced membrane permeability. Resistance genes are often located on plasmids and integrons, allowing rapid dissemination. Therefore, this group should only be used when the bacteria remain susceptible, typically in cases of mild to moderate infections.
6. β-lactam group β-lactam antibiotics exert their bactericidal effect by inhibiting bacterial cell wall synthesis through binding to Penicillin Binding Proteins (PBPs). However, the effectiveness of this group has significantly declined due to the emergence of β-lactamase enzymes, particularly ESBL and AmpC.
Within this group, aminopenicillins such as ampicillin and amoxicillin show high resistance rates, resulting in inconsistent treatment efficacy. Combination with β-lactamase inhibitors may improve effectiveness, but the outcome still depends on the susceptibility of the bacteria. In contrast, cephalosporins, particularly third-generation agents such as ceftiofur, cefotaxime, and ceftriaxone, are more stable against β-lactamase enzymes and still maintain relatively good efficacy. Therefore, this group is often preferred in cases of severe infections. 7. Polypeptide group
The polypeptide group, represented mainly by colistin and polymyxin B, acts by disrupting the bacterial cell membrane through interaction with lipopolysaccharides (LPS). Because these drugs are minimally absorbed through the gastrointestinal tract, they achieve high concentrations in the intestine, making them particularly effective for the treatment of gastrointestinal infections and for controlling pathogens within the flock.
However, when administered orally, polypeptides are not suitable for treating septicemia because they do not reach therapeutic concentrations in the bloodstream. Currently, the resistance rate of E. coli to this group remains relatively low, but the emergence of the plasmid-mediated mcr gene is increasing the risk of future resistance.
Within this group, polymyxin B has a mechanism of action similar to colistin but is less commonly used due to its higher toxicity.
III. Antibiotic Combination Therapy and Treatment Approaches for E. coli Septicemia in Ducks
In practice, the use of a single antibiotic alone often does not provide optimal efficacy, especially in cases of severe infection or when the bacteria have developed resistance. Therefore, combining antibiotics from different groups with distinct mechanisms of action is a commonly applied strategy to enhance treatment effectiveness. However, combinations of antibiotics with similar mechanisms or potential antagonistic effects should be avoided, and the excessive use of multiple antibiotics at the same time should be limited in order to reduce the risk of antimicrobial resistance and toxicity.
Some combination regimens commonly applied in practice include:
- Combination of third-generation cephalosporins and aminoglycosides: This combination provides a strong synergistic effect, enhances bactericidal activity, and is commonly used in severe cases of infection. - Combination of aminopenicillins and aminoglycosides: This combination also provides a synergistic effect; however, due to the high resistance rate of E. coli to aminopenicillins, the treatment efficacy is generally moderate. IV. Effective Treatment Strategies for E. coli Septicemia in Ducks and Measures to Limit Antimicrobial Resistance
The treatment of E. coli septicemia in ducks requires the selection of appropriate antibiotics, with priority given to groups that still maintain good efficacy, such as fluoroquinolones, aminoglycosides, and cephalosporins, while limiting the use of groups with high resistance rates. In severe infections, rational antibiotic combinations may be applied to enhance treatment effectiveness.
In addition to specific antimicrobial therapy, supportive treatment with electrolytes, vitamins, antipyretics, liver and kidney support products, together with proper cleaning and disinfection of the housing environment, should be implemented to promote recovery and reduce pathogen load within the flock. Furthermore, the rational use of antibiotics, preferably based on antimicrobial susceptibility testing results, is an important strategy to improve treatment efficacy and limit the development of antimicrobial resistance.
The article was prepared by the Research and Development Department of Pharmaceuticals – Central Veterinary Medicine Joint Stock Company No.5
Frequently Asked Questions:
1. Which antibiotics are commonly prioritized for the treatment of E. coli septicemia in ducks?
Antibiotic groups that still maintain good efficacy, such as fluoroquinolones, aminoglycosides, and cephalosporins, are commonly prioritized for the treatment of E. coli septicemia in ducks.
2. Should multiple antibiotics be combined when treating E. coli infection in ducks?
Antibiotic combinations may be used in severe infections to improve treatment efficacy. However, they should be combined rationally to avoid drug antagonism and limit antimicrobial resistance.
3. Why is E. coli becoming increasingly difficult to treat?
The main reason is the increasing level of antimicrobial resistance, resulting from improper dosing, incorrect treatment duration, or the overuse of antibiotics in animal farming.
4. Why are third-generation cephalosporins preferred in severe cases?
Third-generation cephalosporins are more stable against β-lactamase enzymes and still maintain good efficacy against many resistant E. coli strains.
5. What solutions does Fivevet provide to support the treatment of E. coli infection in ducks?
Fivevet currently offers a wide range of veterinary products such as Five-AmoxClav, Five-Amoxcol, and Five-Amox.Genta to support the treatment of E. coli infections in ducks, helping to control bacterial infections, reduce mortality rates, and improve farming efficiency.